alpha-synuclein inclusions in Alzheimer and Lewy body diseases

E B Mukaetova-Ladinska, J Hurt, R Jakes, J Xuereb, W G Honer, C M Wischik

Research output: Contribution to journalArticle

Abstract

alpha-Synuclein has assumed particular neuropathological interest in the light both of its identification as a non-beta-amyloid plaque constituent in Alzheimer disease (AD), and the recent association between dominant inheritance of Parkinson disease (PD) and 2 missense mutations at positions 30 and 53 of the synuclein protein. We report a systematic study of alpha-synuclein, tau, and ubiquitin immunoreactivity in representative neurodegenerative disorders of late life. The alpha-synuclein association with Lewy bodies is variable, peripheral, and is not stable with respect to proteases or acid treatment, whereas there is no association with Pick bodies. Stable patterns of immunoreactivity included neurites and a novel inclusion body. Although there is an overlap between the presence of Lewy bodies and stable a-synuclein immunoreactivity, this is seen only in the presence of concomitant neuropathological features of AD. The novel alpha-synuclein inclusion body identified in pyramidal cells of the medial temporal lobe in particular was found in AD and in the Lewy body variant of AD, and was associated neither with ubiquitin nor tau protein. The inclusion is therefore neither a Lewy body nor a PHF-core body, but may be confused with the Lewy body, particularly in the Lewy body variant of AD. Abnormal processing of alpha-synuclein leading to its deposition in the form of proteolytically stable deposits is a particular feature of the intermediate stages of AD.

Original languageEnglish
Pages (from-to)408-417
Number of pages10
JournalJournal of Neuropathology and Experimental Neurology
Volume59
Publication statusPublished - 2000

Keywords

  • Alzheimer disease
  • amyloid deposits
  • alpha-synuclein
  • cortical Lewy body disease
  • neurofibrillary changes
  • A-BETA COMPONENT
  • MULTIPLE SYSTEM ATROPHY
  • CENTRAL-NERVOUS-SYSTEM
  • PARKINSONS-DISEASE
  • PRECURSOR PROTEIN
  • GRANULOVACUOLAR DEGENERATION
  • CYTOPLASMIC INCLUSIONS
  • PRESYNAPTIC PROTEIN
  • SYNAPSE LOSS
  • HUMAN BRAIN

Cite this

Mukaetova-Ladinska, E. B., Hurt, J., Jakes, R., Xuereb, J., Honer, W. G., & Wischik, C. M. (2000). alpha-synuclein inclusions in Alzheimer and Lewy body diseases. Journal of Neuropathology and Experimental Neurology, 59, 408-417.

alpha-synuclein inclusions in Alzheimer and Lewy body diseases. / Mukaetova-Ladinska, E B ; Hurt, J ; Jakes, R ; Xuereb, J ; Honer, W G ; Wischik, C M .

In: Journal of Neuropathology and Experimental Neurology, Vol. 59, 2000, p. 408-417.

Research output: Contribution to journalArticle

Mukaetova-Ladinska, EB, Hurt, J, Jakes, R, Xuereb, J, Honer, WG & Wischik, CM 2000, 'alpha-synuclein inclusions in Alzheimer and Lewy body diseases', Journal of Neuropathology and Experimental Neurology, vol. 59, pp. 408-417.
Mukaetova-Ladinska, E B ; Hurt, J ; Jakes, R ; Xuereb, J ; Honer, W G ; Wischik, C M . / alpha-synuclein inclusions in Alzheimer and Lewy body diseases. In: Journal of Neuropathology and Experimental Neurology. 2000 ; Vol. 59. pp. 408-417.
@article{1628f79875f247669b78be3652c3fd92,
title = "alpha-synuclein inclusions in Alzheimer and Lewy body diseases",
abstract = "alpha-Synuclein has assumed particular neuropathological interest in the light both of its identification as a non-beta-amyloid plaque constituent in Alzheimer disease (AD), and the recent association between dominant inheritance of Parkinson disease (PD) and 2 missense mutations at positions 30 and 53 of the synuclein protein. We report a systematic study of alpha-synuclein, tau, and ubiquitin immunoreactivity in representative neurodegenerative disorders of late life. The alpha-synuclein association with Lewy bodies is variable, peripheral, and is not stable with respect to proteases or acid treatment, whereas there is no association with Pick bodies. Stable patterns of immunoreactivity included neurites and a novel inclusion body. Although there is an overlap between the presence of Lewy bodies and stable a-synuclein immunoreactivity, this is seen only in the presence of concomitant neuropathological features of AD. The novel alpha-synuclein inclusion body identified in pyramidal cells of the medial temporal lobe in particular was found in AD and in the Lewy body variant of AD, and was associated neither with ubiquitin nor tau protein. The inclusion is therefore neither a Lewy body nor a PHF-core body, but may be confused with the Lewy body, particularly in the Lewy body variant of AD. Abnormal processing of alpha-synuclein leading to its deposition in the form of proteolytically stable deposits is a particular feature of the intermediate stages of AD.",
keywords = "Alzheimer disease, amyloid deposits, alpha-synuclein, cortical Lewy body disease, neurofibrillary changes, A-BETA COMPONENT, MULTIPLE SYSTEM ATROPHY, CENTRAL-NERVOUS-SYSTEM, PARKINSONS-DISEASE, PRECURSOR PROTEIN, GRANULOVACUOLAR DEGENERATION, CYTOPLASMIC INCLUSIONS, PRESYNAPTIC PROTEIN, SYNAPSE LOSS, HUMAN BRAIN",
author = "Mukaetova-Ladinska, {E B} and J Hurt and R Jakes and J Xuereb and Honer, {W G} and Wischik, {C M}",
year = "2000",
language = "English",
volume = "59",
pages = "408--417",
journal = "Journal of Neuropathology and Experimental Neurology",
issn = "0022-3069",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - alpha-synuclein inclusions in Alzheimer and Lewy body diseases

AU - Mukaetova-Ladinska, E B

AU - Hurt, J

AU - Jakes, R

AU - Xuereb, J

AU - Honer, W G

AU - Wischik, C M

PY - 2000

Y1 - 2000

N2 - alpha-Synuclein has assumed particular neuropathological interest in the light both of its identification as a non-beta-amyloid plaque constituent in Alzheimer disease (AD), and the recent association between dominant inheritance of Parkinson disease (PD) and 2 missense mutations at positions 30 and 53 of the synuclein protein. We report a systematic study of alpha-synuclein, tau, and ubiquitin immunoreactivity in representative neurodegenerative disorders of late life. The alpha-synuclein association with Lewy bodies is variable, peripheral, and is not stable with respect to proteases or acid treatment, whereas there is no association with Pick bodies. Stable patterns of immunoreactivity included neurites and a novel inclusion body. Although there is an overlap between the presence of Lewy bodies and stable a-synuclein immunoreactivity, this is seen only in the presence of concomitant neuropathological features of AD. The novel alpha-synuclein inclusion body identified in pyramidal cells of the medial temporal lobe in particular was found in AD and in the Lewy body variant of AD, and was associated neither with ubiquitin nor tau protein. The inclusion is therefore neither a Lewy body nor a PHF-core body, but may be confused with the Lewy body, particularly in the Lewy body variant of AD. Abnormal processing of alpha-synuclein leading to its deposition in the form of proteolytically stable deposits is a particular feature of the intermediate stages of AD.

AB - alpha-Synuclein has assumed particular neuropathological interest in the light both of its identification as a non-beta-amyloid plaque constituent in Alzheimer disease (AD), and the recent association between dominant inheritance of Parkinson disease (PD) and 2 missense mutations at positions 30 and 53 of the synuclein protein. We report a systematic study of alpha-synuclein, tau, and ubiquitin immunoreactivity in representative neurodegenerative disorders of late life. The alpha-synuclein association with Lewy bodies is variable, peripheral, and is not stable with respect to proteases or acid treatment, whereas there is no association with Pick bodies. Stable patterns of immunoreactivity included neurites and a novel inclusion body. Although there is an overlap between the presence of Lewy bodies and stable a-synuclein immunoreactivity, this is seen only in the presence of concomitant neuropathological features of AD. The novel alpha-synuclein inclusion body identified in pyramidal cells of the medial temporal lobe in particular was found in AD and in the Lewy body variant of AD, and was associated neither with ubiquitin nor tau protein. The inclusion is therefore neither a Lewy body nor a PHF-core body, but may be confused with the Lewy body, particularly in the Lewy body variant of AD. Abnormal processing of alpha-synuclein leading to its deposition in the form of proteolytically stable deposits is a particular feature of the intermediate stages of AD.

KW - Alzheimer disease

KW - amyloid deposits

KW - alpha-synuclein

KW - cortical Lewy body disease

KW - neurofibrillary changes

KW - A-BETA COMPONENT

KW - MULTIPLE SYSTEM ATROPHY

KW - CENTRAL-NERVOUS-SYSTEM

KW - PARKINSONS-DISEASE

KW - PRECURSOR PROTEIN

KW - GRANULOVACUOLAR DEGENERATION

KW - CYTOPLASMIC INCLUSIONS

KW - PRESYNAPTIC PROTEIN

KW - SYNAPSE LOSS

KW - HUMAN BRAIN

M3 - Article

VL - 59

SP - 408

EP - 417

JO - Journal of Neuropathology and Experimental Neurology

JF - Journal of Neuropathology and Experimental Neurology

SN - 0022-3069

ER -